Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Peptidase

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    35 result(s) found for: Peptidase. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2014-001941-25 Sponsor Protocol Number: 2014-002 Start Date*: 2014-12-16
    Sponsor Name:Rigshospitalet 2121
    Full Title: Pilot Study with Treatment of Short Bowel Syndrome Patients with dipeptidyl-peptidase 4 inhibitor, Sitagliptin (Januvia®)
    Medical condition: Short Bowel Syndrome with intestinal failure (SBS IF)
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004856 10022683 Intestinal malabsorption LLT
    17.1 100000004856 10036430 Post surgical malabsorption NOS LLT
    17.1 100000004856 10042822 Syndrome malabsorption LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-001803-22 Sponsor Protocol Number: EFC14867 Start Date*: 2017-12-22
    Sponsor Name:SANOFI-AVENTIS RECHERCHE ET DEVELOPPEMENT
    Full Title: A 26-week Randomized, Double-blind, Controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin compared to Empagliflozin, and Placebo in Patients with Type 2...
    Medical condition: Type 2 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) CZ (Completed) ES (Completed) LV (Completed) SK (Completed) BG (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-004993-40 Sponsor Protocol Number: MK-0431-081 Start Date*: 2015-04-01
    Sponsor Name:Merck & Co., Inc.
    Full Title: A Single-Dose Study to Assess the Pharmacokinetics, Safety, and Tolerability of Sitagliptin in Adolescents
    Medical condition: Type 2 Diabetes Mellitus
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2008-007020-25 Sponsor Protocol Number: 01 Start Date*: 2009-04-03
    Sponsor Name:AMC
    Full Title: Glucose lowering by continuous tube feeding and Vildagliptin in addition to insulin in hyperglycemic acute stroke patients.
    Medical condition: Hyperglycemia in acute ischemic stroke patients
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020635 Hyperglycaemia LLT
    9.1 10023027 Ischaemic stroke NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-001523-31 Sponsor Protocol Number: U1111-1181-4107 Start Date*: 2017-01-30
    Sponsor Name:Steno Diabetes Center Copenhagen
    Full Title: Effect of liraglutide on vascular inflammation in type-2 diabetes: A randomized, placebo-controlled, double-blind, parallel clinical PET/CT trial
    Medical condition: Type 2 diabetes
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10012601 Diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2019-001528-37 Sponsor Protocol Number: Cholzuur Start Date*: 2020-04-09
    Sponsor Name:Cbusinez
    Full Title: Long-term safety study of personalized magistral prepared cholic acid capsules in patients with bile acid synthesis defects
    Medical condition: Patients with phenotypically mild Zellweger Spectrum Disorder (ZSD) or a Single Enzyme Defect (SED) in bile acid synthesis.
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-003339-53 Sponsor Protocol Number: I8H-MC-BDCL Start Date*: 2020-09-22
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 2, Parallel, Comparator-Controlled Trial to Evaluate the Safety and Efficacy of LY3209590 in Insulin-Naïve Patients with Type 2 Diabetes Mellitus
    Medical condition: Diabetes Mellitus, Type 2
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2007-004864-29 Sponsor Protocol Number: F3Z-EW-IOPJ Start Date*: 2008-02-13
    Sponsor Name:Eli Lilly and Company
    Full Title: A Prospective Randomized Trial to Compare Basal Bolus therapies that use either Insulin Lispro Protamine Suspension or Insulin Glargine together with Lispro Insulin in Patients with Type 2 Diabetes
    Medical condition: Type II diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    9.1 10063624 Type II diabetes mellitus inadequate control LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) GR (Completed) GB (Completed) BE (Completed) SK (Completed) IT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-004045-33 Sponsor Protocol Number: PXL008-008 Start Date*: 2012-12-18
    Sponsor Name:Poxel S.A.
    Full Title: A dose-ranging, randomized, double-blind, placebo-controlled, parallel-group, multi-center study of the efficacy and safety of 4 doses of imeglimin after 24 weeks of treatment in subjects with type...
    Medical condition: Type 2 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    16.0 10027433 - Metabolism and nutrition disorders 10012607 Diabetes mellitus inadequate control PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) HU (Completed) EE (Completed) CZ (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2020-005438-14 Sponsor Protocol Number: TAK-062-2001 Start Date*: Information not available in EudraCT
    Sponsor Name:TAKEDA
    Full Title: A Phase 2, Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of TAK-062 for the Treatment of Active Celiac Disease in Subjects Attempting a Gluten...
    Medical condition: Active Celiac Disease in subjects attempting a Gluten-Free Diet
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10009839 Coeliac disease PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing) ES (Temporarily Halted) Outside EU/EEA NL (Ongoing) BE (Ongoing) PL (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-022304-50 Sponsor Protocol Number: NN1250-3847 Start Date*: 2011-02-02
    Sponsor Name:Novo Nordisk A/S
    Full Title: A trial comparing the efficacy and safety of insulin degludec three times weekly in insulin naïve subjects with type 2 diabetes mellitus when titrated using two different titration algorithms
    Medical condition: Type 2 Diabetes
    Disease: Version SOC Term Classification Code Term Level
    12.1 10067585 Type 2 diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) HU (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-000300-89 Sponsor Protocol Number: DSSita-01 Start Date*: 2008-05-07
    Sponsor Name:Cambridge University Hospitals NHS Foundation Trust
    Full Title: The effects of sitagliptin (Januvia) on myocardial performance in patients with coronary artery disease and diabetes
    Medical condition: coronary artery disease and type 2 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    9.1 10011085 Ischaemic coronary artery disorders HLT
    9.1 10012613 Diabetes mellitus non-insulin-dependent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-002569-16 Sponsor Protocol Number: I8H-MC-BDCU Start Date*: 2022-05-20
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 3, Multicenter, Randomized, Parallel-Design, Open-Label Trial to Evaluate the Efficacy and Safety of LY3209590 Compared with Insulin Degludec in Participants with Type 2 Diabetes Currently ...
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Ongoing) HU (Ongoing) ES (Ongoing) PL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-003131-30 Sponsor Protocol Number: EFC12404 Start Date*: 2014-01-22
    Sponsor Name:sanofi-aventis recherche & développement
    Full Title: A randomized, 30 week, active-controlled, open-label, 3-treatment arm, parallel-group multicenter study comparing the efficacy and safety of insulin glargine/ lixisenatide fixed ratio combination t...
    Medical condition: Type II Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    17.0 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) BE (Completed) IT (Completed) EE (Completed) SE (Completed) LT (Completed) LV (Completed) CZ (Completed) ES (Completed) HU (Completed) DK (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2016-002801-20 Sponsor Protocol Number: NN1250-4252 Start Date*: 2017-02-10
    Sponsor Name:Novo Nordisk A/S
    Full Title: A trial comparing the efficacy and safety of insulin degludec and insulin glargine 300 units/mL in subjects with type 2 diabetes mellitus inadequately treated with basal insulin with or without ora...
    Medical condition: Diabetes Mellitus, Type 2
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) DK (Completed) EE (Completed) GR (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2012-000619-10 Sponsor Protocol Number: RUNMC-EX-BCM-2012 Start Date*: 2012-07-24
    Sponsor Name:Radboud University Nijmegen Medical Centre
    Full Title: Clinical proof-of-principle of the determination of the beta cell mass in vivo by SPECT imaging with the 111In-labeled GLP-1 analogue DTPA-[K40]-Exendin 4
    Medical condition: patients with long-standing type 1 diabetes
    Disease: Version SOC Term Classification Code Term Level
    14.1 10014698 - Endocrine disorders 10018424 Glucose metabolism disorders (incl diabetes mellitus) HLGT
    14.1 10014698 - Endocrine disorders 10012602 Diabetes mellitus (incl subtypes) HLT
    14.1 10027433 - Metabolism and nutrition disorders 10012601 Diabetes mellitus PT
    14.1 10027433 - Metabolism and nutrition disorders 10067584 Type 1 diabetes mellitus PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-004768-12 Sponsor Protocol Number: NN5401-4266 Start Date*: 2016-08-10
    Sponsor Name:Novo Nordisk A/S
    Full Title: A 38 week trial comparing effect and safety of insulin degludec/insulin aspart vs. insulin glargine plus insulin aspart in subjects with type 2 diabetes treated with basal insulin with or without o...
    Medical condition: Diabetes Mellitus, Type 2
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2012-005583-10 Sponsor Protocol Number: NN1218-4049 Start Date*: 2013-05-15
    Sponsor Name:Novo Nordisk A/S
    Full Title: Efficacy and safety of FIAsp in a basal-bolus regimen versus basal insulin therapy, both in combination with metformin in adult Subjects with type 2 diabetes
    Medical condition: Diabetes Mellitus, Type 2
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SI (Completed)
    Trial results: View results
    EudraCT Number: 2020-000472-37 Sponsor Protocol Number: NN1436-4479 Start Date*: 2020-12-17
    Sponsor Name:Novo Nordisk A/S
    Full Title: A 26-week double blinded, multiregional, trial comparing the effect and safety of once weekly insulin icodec and once daily insulin degludec 100 units/mL, both in combination with non-insulin anti-...
    Medical condition: Diabetes Mellitus, Type 2
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) AT (Completed) DK (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2020-000476-38 Sponsor Protocol Number: NN1436-4481 Start Date*: 2021-03-01
    Sponsor Name:Novo Nordisk A/S
    Full Title: Effectiveness and safety of once weekly insulin icodec used with DoseGuide versus once daily basal insulin analogues in an insulin naïve type 2 diabetes population in a clinical practice setting
    Medical condition: Diabetes Mellitus, Type 2
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) GR (Completed) PL (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 01:03:57 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA